北京长期痛风的危害有哪些(北京老人痛风怎么办) (今日更新中)

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

SINGAPORE, July 10 (Xinhua) -- The upcoming Natural History Museum in Singapore launched a drive on Sunday to raise 12 million Singapore dollars (9.8 million U.S. dollars) by the end of the month to buy three dinosaur fossils from a company in Wyoming, the United States.The three dinosaurs on offer from the company Dinosauria International, thought to be a family, were found between 2007 and last year in the United States, the Straits Times reported on Sunday.Appollo and Prince, the two adult diplodocid sauropods, is about 24 meters long, while the baby Twinky is about 12 meters.The natural history museum is expected to be completed by 2014. The three dinosaur fossils will cost 870 million Singapore dollars, and an additional 370 million Singapore dollars will be spent to set up the exhibition."They wanted the museum to tell the story of the history of life and evolution. Dinosaurs are the history of life," said Professor Peter Ng, director of the Raffles Museum of Biodiversity Research, referring to the approval from the scientific advisory committee for the acquisition.The Raffles Museum of Biodiversity Research of the National University of Singapore went on an intensive fund raising campaign last year to build the dedicated Natural History Museum.The museum said it has found the amount to be challenging. It is therefore appealing for help from the public through the media."The idea was always to have a central gallery and put something there that would make people go 'Whoa!,'" said Ng.

XICHANG, Sichuan, June 21 (Xinhua) -- China successfully launched a new communication satellite, the Zhongxing-10, from its Xichang Satellite Launch Center in southwest Sichuan Province on early Tuesday.The satellite, carried by a Long March-3B rocket carrier, blasted off from the center at 0:13 a.m., said a statement from the center.According to statistics from the control center, the satellite successfully separated from its carrier rocket and entered Earth's orbit as scheduled, 26 minutes after being launched.The Zhongxing-10 was designed and manufactured by the China Academy of Space Technology under the China Aerospace Science and Technology Corporation.The satellite will provide communication, broadcasting and data transmission services for users in China and the Asia-Pacific region. It will replace the Zhongxing-5B satellite, which was launched in 1998.The launch was the 138th mission for the Long March carrier rocket series.

HAVANA, Aug. 15 (Xinhua) -- Cuba's Ministry of Public Health launched an intensive sanitation campaign Monday against the Aedes Aegypti mosquito, which can spread dengue fever.The operation, which is running through Sept. 15, will cover the most vulnerable cities in the country, including the capital Havana and the eastern city Guantanamo.Deputy Health Minister Luis Estruch stressed the importance of the prevention campaign and urged all families to check their houses for mosquitoes each week.Maria Guadalupe Guzman, director of the Pan-American and World Health Organization Cooperation Center for the Study of Dengue and Its Vector at the Pedro Kouri Institute of Tropical Medicine, said the epidemiological situation in the country is stable. However, she warned that an epidemic outbreak is still possible in the island state, given the high temperatures and heavy rains in the eastern areas, and drought in the west.Cuba, along with Chile and Uruguay, are the only Latin American countries where dengue is not endemic.In 1981, the country suffered its worst dengue outbreak in history, which left 158 dead.

BEIJING, Aug. 1 (Xinhua) -- The after-tax CIF (cost, insurance and freight) price of China's jet fuel imports has been set at 7,768 yuan (1,206 U.S. dollars) per metric ton for August, China's economic planner said on Monday.The price adjustment marked the first time for the economic planner to adjust jet fuel prices on a monthly basis after it announced jet fuel pricing reforms in July, according to a notice posted on the National Development and Reform Commission (NDRC)'s website.The NDRC announced on July 7 that it would introduce a market-oriented jet fuel pricing mechanism starting from Aug. 1.Under the new mechanism, the ex-plant price of jet fuel is required to be no higher than the after-tax CIF price of jet fuel imports from Singapore, Asia's largest oil trading and storage center.Taking transportation expenses, trade volumes and international crude oil prices into account, the jet fuel premium is negotiable between jet fuel sellers and buyers and will be reviewed once a year, while jet fuel ex-plant prices will be adjusted on the first day of every month, according to the NDRC.

来源：资阳报